Prognostic value of pretreatment systemic immune-inflammation index in patients with endometrial cancer: a meta-analysis

Abstract

Background: The present work focused on evaluating the systemic immune-inflammation index (SII) for its role in predicting endometrial cancer (EC) patient prognosis by meta-analysis. Methods: SII's role in predicting the prognosis of EC patients was analyzed by calculating combined hazard ratios (HRs) and 95% CIs. Results: As revealed by combined analysis, an increased SII predicted poor overall survival (HR = 2.01; 95% CI = 1.58–2.57; p < 0.001) as well as inferior progression-free survival (HR = 1.87; 95% CI = 1.36–2.58; p < 0.001) of EC. Conclusion: An increased SII score significantly predicted poor overall survival and progression-free survival in subjects with EC. The SII is suitable for predicting short- and long-term prognoses of patients with EC.

Summary points

• Previous studies have explored the role of systemic immune-inflammation index (SII) in predicting endometrial cancer (EC) prognosis; however, consistent findings have not been reported.

• The SII has been recognized to be a novel inflammatory biomarker, determined by the number of platelets × neutrophils/lymphocytes.

• This meta-analysis is the first to explore the utility of the SII in predicting prognosis of patients with EC.

• An increased SII predicted poor overall survival as well as inferior progression-free survival of EC.

• The pooled results revealed no significant changes after each study was excluded, thus supporting the robustness of the findings.

• There was no obvious publication bias in this meta-analysis.

• The SII can be used to predict short- and long-term prognoses in this patient population of EC.

• Large-scale studies using uniform cutoff values to validate our observations are warranted.

Keywords: :

• endometrial cancer
• evidence-based medicine
• meta-analysis
• prognosis
• systemic immune-inflammation index

Author contributions

P Ji and J He searched the database and analyzed the data. P Ji and J He selected the study and extracted the data. P Ji wrote the manuscript. J He reviewed the manuscript. All authors contributed to the article and approved the submitted version.

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.

Writing disclosure

Medical writing support was provided by Editage and was funded by the authors.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.